Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET

Company Participants

Christian Kanstrup – Chief Executive Officer
Birgitte Rono – Chief Scientific Officer
Jesper Nissen – Chief Operating Officer and Chief Financial Officer

Conference Call Participants

Ahu Demir – Ladenburg Thalmann
Swayampakula Ramakanth – H.C. Wainwright
Thomas Flaten – Lake Street Capital Markets
Richard Ramanius – Redeye

Christian Kanstrup

Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results. I’m Christian Kanstrup. I’m the CEO of Evaxion. With me today, I have Birgitte Rono, our Chief Scientific Officer. I have Jesper Nissen, our Chief Operating Officer and Chief Financial Officer. What we will be covering today is I will be giving a brief welcome, also a brief corporate update. Then, we will have Birgitte dive into the R&D and business update, and Jesper will be covering the 2023 financial results.

After a few conclusive remarks by me, we will be heading into the Q&A session. So, looking forward to an interactive session. Before getting started, I just want to direct your attention to the fact that we will be talking about the future today. And of course, when talking about the future that entails uncertainty. So, I do direct your attention to the forward-looking statement slide, which is contained in the presentation deck for today.

With that, let me give you a brief summary of where we are today. First of all, we have refined our strategy. We have launched it and it’s well anchored. And just to remind you, this is about our three-pronged business model, and I would touch upon it in a few seconds. Then we have also seen strong progress on our financing strategy.

We have now